Seeking Alpha
Growth, momentum, long-term horizon, newsletter provider
Profile| Send Message|
( followers)  

In response to a number of requests that I've received via email or comments asking for 'VFC's Take' on numerous stocks that readers of have found, I'll do my best to address as many as I can, as long as everyone takes a few things into account while reading:

- I have not thoroughly researched all of the stocks that I'm about to comment on. I've done the initial DD but my opinions are mostly based on my first impressions of the stock. I'm merely providing VFC's Take, as requested. Use that as a starting point to do your own DD.

- Don't get testy if I don't like your stock. Remember, this is just my initial impression and I take into consideration some variables that other people don't, that's why VFC's Take is not always the mainstream impression.

- I appreciate all the recent feedback, and keep the stock tips coming; this is a great forum for all investors of all levels to share tips and insights. There's a whole lot of stocks out there, but there's only a few gems. Let's keep trying to find those gems.

ANX: AdventRX Pharmaceuticals:

A comment from Lenny in sunny Australia:

Hope you are having a relaxing weekend! Melbourne Australia is a lovely place, and considering it is middle of winter yet has temperatures of around 50-60 Fahrenheit, who can complain? While having a drink I made a toast to your health! (-:

If you get a chance, can you please have a look at ANX? It has a market cap under 20 million with no debt, appears to be 'under the radar', and has an interesting product (it does not appear to be a '1 trick pony'). It is a product reformulation (which may reduce its risk?) and looks to have benefits over what is being currently used in chemo.

Let us know when you get a chance.

Tks!

Lenny

Thanks for the toast, Lenny. Much appreciated. I've never hit Melbourne myself and you can't complain about weather like that in the "middle of winter!" Enjoy!

VFC's Take: About a month ago I responded to another inquiry regarding ANX and I will maintain my stance that it is a decent speculative buy for the reasons listed above by Lenny. I do believe that the company is still trading somewhat 'below the radar,' but also note the increasing volume of late.

The time for getting in may be slowly disappearing as the stock has risen to twenty cents from fourteen cents in just over a few weeks. It should go higher as the date for the NDA submission for ANX-530, scheduled to take place by the end of this year, approaches.

However, with ANX-530 being a reformulation of an existing product, I'd be a bit weary of long term viability unless it brings something significantly new to the table. That being said, the market cap is fairly small, in my opinion, and could at least double leading into the NDA filing.

Personally, I'd treat this stock as a mid term trade vice a long term hold - for now; definitely worth buying a few shares and seeing what happens, in my opinion.

Disclosure: VFC is long ANX.


OTC:SPNG Spongetech, FNM Fannie Mae, FRE Freddie Mac:

From Pixie:

Woo hoo, go SPNG! Suddenly I realize SPNG is everywhere. I caught their ads on WETA Kids, Nickelodeon and CNBC recently. Ever since she saw the ad, my daughter's been pestering me to buy this cool Spongebob sponge. Should I be the frugal mom or help the stock by shelling out 14 bucks? LOL.

What's your take on FNM and FRE, both of which rebounded some, though nothing on the lines of AIG...

Thanks much!
Pixie


VFC's Take: Regarding SPNG, the company is going all out on the marketing front. Quite simply - the marketing will translate into nice sales numbers and handsomely reward shareholders or it will fruitlessly eat into existing cash and burn the company into the ground if the full fledged marketing attack does not translate into revenue.

Keep in mind that if the current marketing blitz does NOT translate into big sales, then a reverse split may be in order. If that occurs, I'd add shares on any dip post-split.

For the time being, I can support an argument for continued buying at twenty cents.

FNM, FRE: An eventual rebound is likely from both, but these companies are extreme messes and too closely associated with the federal government for me to feel comfortable putting my money in there.

Rebound stories are everywhere and I'd personally look elsewhere before considering these two as safe investments, although keep in mind I said the same thing about AIG - so do your own DD and invest accordingly.

Disclosure: Long SPNG, no position FRM, FNE.

Doubleday Book Club (Direct Agents)- dbc300x250OTC:EPCT: EpiCept Corp.

From an anonymous poster:

Did you get out of EPCT? You have indicated a few times that you have been considering getting out.


VFC's Take: It's true that I've been considering getting out of EPCT for some time, but I've also stated that I'm going to hold on until the next update on Azixa is released.

Azixa, a treatment for brain cancer, is partnered with Myriad and positive updates on that drug candidate have launched the EPCT stock price to over four dollars in the past.

I haven't completely written off Ceplene yet, but the lack of relevant news regarding a European partner is somewhat troubling and I'm not going to bank the future of my EPCT investment on that product.

EPCT still holds quite a bit of potential, in my opinion, and I'm still in - for the time being.

Disclosure: VFC is long EPCT.

Source: Readers Ask: AdventRX. Fannie Mae, Freddie Mac, EpiCept